

Jeffrey I Weitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918408/publications.pdf>

Version: 2024-02-01

520
papers

63,796
citations

1299

109
h-index

911

241
g-index

538
all docs

538
docs citations

538
times ranked

38014
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciraparantag as a potential universal anticoagulant reversal agent. <i>European Heart Journal</i> , 2022, 43, 993-995.	1.0	3
2	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. <i>Kidney International Reports</i> , 2022, 7, 200-209.	0.4	31
3	Producing Fluorine- and Lubricant-Free Flexible Pathogen- and Blood-Repellent Surfaces Using Polysiloxane-Based Hierarchical Structures. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 3864-3874.	4.0	8
4	Identification of the histidine-rich glycoprotein domains responsible for contact pathway inhibition. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 821-832.	1.9	3
5	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. , 2022, 1, .		13
6	Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions. <i>Small</i> , 2022, 18, e2108112.	5.2	4
7	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1279-1287.	1.8	11
8	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	1.4	5
9	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
10	ISTH Biennial Impact Report: Looking back and looking forward. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1515-1517.	1.9	0
11	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. <i>TH Open</i> , 2022, 06, e177-e183.	0.7	1
12	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. <i>Annals of Surgery</i> , 2021, 274, e204-e211.	2.1	27
13	New anticoagulants: Moving beyond the direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 20-29.	1.9	45
14	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	2.0	11
15	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
16	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	1.0	6
17	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	1.0	23
18	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1684-1695.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
20	Factor XI as a Target for New Anticoagulants. <i>Hamostaseologie</i> , 2021, 41, 104-110.	0.9	48
21	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	0.8	14
22	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1546-1557.	1.9	45
23	International Society on Thrombosis and Haemostasis: Present and future. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1599-1601.	1.9	0
24	The contact activation inhibitor ABO23 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2173-2184.	0.6	56
25	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 203, 155-162.	0.8	9
26	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 609-617.	13.9	143
27	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2801-2813.	1.9	19
28	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis. <i>Journal of the American College of Cardiology</i> , 2021, 78, 625-631.	1.2	78
29	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780.	1.9	4
30	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	1.9	10
31	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
32	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2021, 174, 1420-1429.	2.0	60
33	Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. <i>Blood Advances</i> , 2021, 5, 3540-3551.	2.5	11
34	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	2.6	23
35	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.	1.9	14
36	Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 541-552.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1612.	2.6	326
38	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, , .	1.9	8
39	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	3
40	Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. <i>Blood</i> , 2021, 138, 3024-3024.	0.6	0
41	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. , 2021, 3, e0588.		11
42	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 2161-2172.	13.9	122
43	Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. <i>Annals of Thoracic Surgery</i> , 2020, 110, 582-590.	0.7	15
44	Hospitalized COVID-19 Patients and Venous Thromboembolism. <i>Circulation</i> , 2020, 142, 129-132.	1.6	50
45	Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. <i>Biomaterials</i> , 2020, 258, 120291.	5.7	72
46	COVID-19 coagulopathy, thrombosis, and bleeding. <i>Blood</i> , 2020, 136, 381-383.	0.6	96
47	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	2.8	28
48	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
49	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	0.6	106
50	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147.	1.2	50
51	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 847-856.	1.8	20
52	Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2364-2376.	1.9	11
53	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1661-1671.	1.9	10
54	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 333-352.	21.5	188

#	ARTICLE	IF	CITATIONS
55	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	1.0	54
56	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	3.1	31
57	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
58	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 515-524.	1.8	16
59	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.	3.8	146
60	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020, 191, 103-112.	0.8	22
61	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 1-11.	1.0	10
62	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 20-29.	1.0	14
63	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.	1.0	6
64	The contact activation system as a potential therapeutic target in patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 500-505.	1.0	33
65	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
66	Novel antithrombotic strategies for treatment of venous thromboembolism. <i>Blood</i> , 2020, 135, 351-359.	0.6	51
67	Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. <i>Journal of Trauma and Acute Care Surgery</i> , 2020, 89, e177-e181.	1.1	7
68	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Blood</i> , 2020, 136, 23-24.	0.6	2
69	Recent advances in understanding, diagnosing and treating venous thrombosis. <i>F1000Research</i> , 2020, 9, 1206.	0.8	5
70	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020, 04, e446-e456.	0.7	11
71	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986364.	1.0	6
72	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	1.8	34

#	ARTICLE	IF	CITATIONS
73	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177
74	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1866-1874.	1.9	42
75	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
76	Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. <i>Thrombosis Research</i> , 2019, 184, 44-49.	0.8	8
77	Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 6485-6496.	2.6	32
78	Are Ticks the Answer to Medical-Device-Associated Clotting?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2190-2192.	1.2	3
79	Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2081-2088.	1.9	4
80	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	1.2	24
81	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. <i>Circulation Research</i> , 2019, 124, 416-425.	2.0	29
82	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	2.0	76
83	Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. <i>Circulation Research</i> , 2019, 124, 351-353.	2.0	9
84	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , 2019, 124, e119.	2.0	2
85	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. <i>Acta Biomaterialia</i> , 2019, 94, 2-10.	4.1	148
86	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	1.9	30
87	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
88	Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. <i>Thrombosis and Haemostasis</i> , 2019, 119, 992-999.	1.8	15
89	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019, 139, 2170-2185.	1.6	66
90	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , 2019, 380, 1825-1833.	13.9	96

#	ARTICLE	IF	CITATIONS
91	Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 981-991.	1.8	33
92	AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 533-535.	1.1	7
93	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019, 104, e474-e477.	1.7	1
94	Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. <i>Scientific Reports</i> , 2019, 9, 2436.	1.6	10
95	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. , 2019, , 1067-1077.		0
96	MAA868 locks factor XIa in a zymogen-like state. <i>Blood</i> , 2019, 133, 1393-1394.	0.6	8
97	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. <i>Thrombosis and Haemostasis</i> , 2019, 119, 689-694.	1.8	11
98	Rivaroxaban for prevention and treatment of venous thromboembolism. <i>Future Cardiology</i> , 2019, 15, 63-77.	0.5	7
99	Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach. , 2019, 1, e0032.		15
100	Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. <i>Small</i> , 2019, 15, e1905562.	5.2	31
101	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
102	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
103	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 461-466.	1.8	11
104	Advances in Antithrombotic Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 7-12.	1.1	42
105	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. <i>Blood</i> , 2019, 134, 163-163.	0.6	8
106	Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial. <i>Blood</i> , 2019, 134, 3669-3669.	0.6	0
107	Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 413-417.	1.9	9
108	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62

#	ARTICLE	IF	CITATIONS
109	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116
110	2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 304-310.	1.1	31
111	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14.	0.8	20
112	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008.	1.8	18
113	Global public awareness about atrial fibrillation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 49-57.	1.0	9
114	Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. <i>European Journal of Haematology</i> , 2018, 101, 3-11.	1.1	13
115	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , 2018, 118, S23-S33.	1.8	12
116	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
117	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
118	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	0.7	46
119	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	0.7	5
120	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. <i>Annals of Emergency Medicine</i> , 2018, 71, 314-325.e1.	0.3	47
121	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
122	Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2338-2344.	1.1	10
123	Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. <i>ACS Nano</i> , 2018, 12, 10890-10902.	7.3	83
124	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. <i>Blood Advances</i> , 2018, 2, 1806-1806.	2.5	1
125	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	2.5	71
126	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018, 2, 3193-3195.	2.5	0

#	ARTICLE	IF	CITATIONS
127	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. <i>TH Open</i> , 2018, 02, e190-e201.	0.7	14
128	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	13.9	730
129	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 413-418.	0.6	6
130	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973.	1.6	32
131	Antithrombotic Drugs. , 2018, , 2168-2188.		5
132	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
133	Hematologic Problems in the Surgical Patient. , 2018, , 2304-2312.e4.		2
134	Overview of Hemostasis and Thrombosis. , 2018, , 1831-1842.		8
135	Conductive Electrochemically Active Lubricantâ€infused Nanostructured Surfaces Attenuate Coagulation and Enable Frictionâ€Less Droplet Manipulation. <i>Advanced Materials Interfaces</i> , 2018, 5, 1800617.	1.9	38
136	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11
137	Gastrointestinal Bleeding With Edoxaban Versus Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003998.	0.9	33
138	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	0.8	4
139	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
140	Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1116-1119.	0.8	6
141	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2527-2527.	0.6	4
142	Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thromboprophylaxis. <i>Blood</i> , 2018, 132, 1236-1236.	0.6	0
143	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ„¢ study. <i>Journal of Medical Economics</i> , 2017, 20, 435-442.	1.0	7
144	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , 2017, 4, e105-e113.	2.2	112

#	ARTICLE	IF	CITATIONS
145	Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 040-050.	0.8	13
146	Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. <i>Stroke</i> , 2017, 48, 1432-1437.	1.0	79
147	Anticoagulation for Mechanical Heart Valves. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 743-745.	1.1	17
148	Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 2491-2492.	13.9	2
149	Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. <i>Scientific Reports</i> , 2017, 7, 2102.	1.6	37
150	Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex. <i>Biochemistry</i> , 2017, 56, 3119-3128.	1.2	12
151	Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e254-e255.	2.2	0
152	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
153	Platelet polyphosphate: the long and the short of it. <i>Blood</i> , 2017, 129, 1574-1575.	0.6	22
154	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
155	Emerging anticoagulant strategies. <i>Blood</i> , 2017, 129, 147-154.	0.6	58
156	Dabigatran Reversal with Idarucizumab. <i>New England Journal of Medicine</i> , 2017, 377, 1690-1692.	13.9	23
157	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2411-2420.	1.2	342
158	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2377-2387.	1.9	19
159	An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. <i>Scientific Reports</i> , 2017, 7, 11639.	1.6	86
160	Research and Practice in Thrombosis and Haemostasis - a new ISTH publishing platform for the global thrombosis and hemostasis community. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 6-8.	1.0	0
161	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. <i>Annals of Internal Medicine</i> , 2017, 167, JC17.	2.0	0
162	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858

#	ARTICLE	IF	CITATIONS
163	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
164	Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2213-2214.	1.8	1
165	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2406-2414.	1.8	8
166	New developments in anticoagulants: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1283-1288.	1.8	81
167	Factors XI and XII as Targets for New Anticoagulants. <i>Frontiers in Medicine</i> , 2017, 4, 19.	1.2	69
168	Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. <i>F1000Research</i> , 2017, 6, 985.	0.8	22
169	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1509-1517.	1.8	2
170	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	1.8	11
171	Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. <i>Thrombosis and Haemostasis</i> , 2016, 115, 533-542.	1.8	30
172	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 809-816.	1.8	16
173	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	1.8	24
174	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. <i>Thrombosis and Haemostasis</i> , 2016, 116, S33-S40.	1.8	8
175	Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. <i>Thrombosis and Haemostasis</i> , 2016, 115, 89-98.	1.8	42
176	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1159-1164.	1.8	16
177	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248.	1.8	64
178	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	1.8	46
179	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	2.7	83
180	Prosthetic Heart Valve Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2670-2689.	1.2	332

#	ARTICLE	IF	CITATIONS
181	A PoTENTIAL Antidote. <i>Circulation Research</i> , 2016, 119, 1157-1160.	2.0	3
182	792 Do Concurrent Gastroprotective Agents Impact Gastrointestinal Bleeding Rates in Edoxaban Users? Results From the ENGAGE-AF TIMI 48 Trial. <i>Gastroenterology</i> , 2016, 150, S165.	0.6	0
183	Factor XI and factor XII as targets for new anticoagulants. <i>Thrombosis Research</i> , 2016, 141, S40-S45.	0.8	60
184	Advances in Thrombosis and Hemostasis. <i>Circulation Research</i> , 2016, 118, 1337-1339.	2.0	12
185	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
186	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	2.0	96
187	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. <i>American Heart Journal</i> , 2016, 177, 74-86.	1.2	42
188	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	2.2	29
189	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematology</i> , 2016, 3, e379-e387.	2.2	136
190	Ciraparantag for enoxaparin reversal: Adding to the evidence. <i>Thrombosis Research</i> , 2016, 146, 106-107.	0.8	6
191	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". <i>Circulation</i> , 2016, 134, e498.	1.6	0
192	Appropriate Apixaban Dosing. <i>JAMA Cardiology</i> , 2016, 1, 635.	3.0	16
193	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , 2016, 134, 186-188.	1.6	47
194	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 29-35.	0.7	2
195	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 241-250.	1.8	9
196	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	1.8	28
197	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016, 144, 158-164.	0.8	4
198	Idarucizumab for dabigatran overdose. <i>Clinical Toxicology</i> , 2016, 54, 644-646.	0.8	30

#	ARTICLE	IF	CITATIONS
199	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	1.3	0
200	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology, 2016, 3, e228-e236.	2.2	55
201	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. Canadian Journal of Cardiology, 2016, 32, 1332-1339.	0.8	7
202	Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. PLoS ONE, 2016, 11, e0157471.	1.1	12
203	Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants. Polish Archives of Internal Medicine, 2016, 126, 688-696.	0.3	11
204	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thrombosis Research, 2015, 136, S13-S18.	0.8	4
205	Medical device-induced thrombosis: what causes it and how can we prevent it?. Journal of Thrombosis and Haemostasis, 2015, 13, S72-S81.	1.9	374
206	Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood, 2015, 125, 2712-2719.	0.6	40
207	Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis, 2015, 13, 2187-2191.	1.9	175
208	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	1.8	48
209	Edoxaban for treatment of venous thromboembolism in patients with cancer. Thrombosis and Haemostasis, 2015, 114, 1268-1276.	1.8	79
210	Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. Thrombosis and Haemostasis, 2015, 113, 1278-1288.	1.8	20
211	Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. Shock, 2015, 44, 166-172.	1.0	92
212	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thrombosis and Haemostasis, 2015, 114, 1113-1126.	1.8	59
213	Timing the First Postoperative Dose of Anticoagulants. Chest, 2015, 148, 587-595.	0.4	15
214	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis, 2015, 114, 198-205.	1.8	132
215	“Real world” use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thrombosis and Haemostasis, 2015, 113, 1159-1161.	1.8	18
216	Novel oral anticoagulants and reversal agents: Considerations for clinical development. American Heart Journal, 2015, 169, 751-757.	1.2	69

#	ARTICLE	IF	CITATIONS
217	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	1.6	141
218	Anticoagulation therapy in 2015: where we are and where we are going. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 264-272.	1.0	12
219	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	13.9	1,419
220	Factor XI Antisense Oligonucleotide for Venous Thrombosis. <i>New England Journal of Medicine</i> , 2015, 372, 1671-1672.	13.9	16
221	Overview of the New Oral Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1056-1065.	1.1	155
222	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15006.	18.1	216
223	Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2544-2553.	1.1	127
224	Trends in Prescribing Oral Anticoagulants in Canada, 2008â€”2014. <i>Clinical Therapeutics</i> , 2015, 37, 2506-2514.e4.	1.1	124
225	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valveâ€”Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , 2015, 4, e002322.	1.6	78
226	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. <i>New England Journal of Medicine</i> , 2015, 372, 232-240.	13.9	497
227	Transition from apixaban to warfarinâ€”addressing excess stroke, systemic embolism, and major bleeding. <i>American Heart Journal</i> , 2015, 169, 1-3.	1.2	11
228	Abstract 17392: Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2015, 132, .	1.6	5
229	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1141-1152.	1.8	26
230	Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. <i>Thrombosis and Haemostasis</i> , 2014, 112, 412-418.	1.8	21
231	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. <i>Thrombosis and Haemostasis</i> , 2014, 112, 79-86.	1.8	14
232	Reduced Plasminogen Binding and Delayed Activation Render Î³â€”Fibrin More Resistant to Lysis than Î²A-Fibrin. <i>Journal of Biological Chemistry</i> , 2014, 289, 27494-27503.	1.6	10
233	Thrombosis: A Major Contributor to Global Disease Burden. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 724-735.	1.5	103
234	Vorapaxar, Combination Antiplatelet Therapy, and Strokeâ€” . <i>Journal of the American College of Cardiology</i> , 2014, 64, 2327-2329.	1.2	3

#	ARTICLE	IF	CITATIONS
235	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. <i>Blood</i> , 2014, 124, 1020-1028.	0.6	114
236	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	1.9	181
237	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	1.0	25
238	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	1.8	142
239	Periprocedural Management of New Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. <i>Circulation</i> , 2014, 129, 1688-1694.	1.6	21
240	Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. <i>Blood</i> , 2014, 123, 2102-2107.	0.6	136
241	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet</i> , The, 2014, 383, 955-962.	6.3	3,942
242	Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	0.7	1
243	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
244	The mTORC Pathway in the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 369-371.	13.9	16
245	Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2363-2371.	1.1	659
246	Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1977-1984.	1.1	379
247	The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. <i>Circulation</i> , 2014, 130, 1636-1661.	1.6	446
248	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 924-931.	1.8	39
249	Non-Vitamin K Antagonist Oral Anticoagulants. <i>Chest</i> , 2014, 145, 1177-1178.	0.4	17
250	Plasma fibronectin supports hemostasis and regulates thrombosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 4281-4293.	3.9	147
251	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. <i>Blood</i> , 2014, 124, 1543-1543.	0.6	4
252	Expanding use of new oral anticoagulants. <i>F1000prime Reports</i> , 2014, 6, 93.	5.9	15

#	ARTICLE	IF	CITATIONS
253	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. <i>Blood</i> , 2014, 124, LBA-1-LBA-1.	0.6	0
254	The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. <i>BMC Biochemistry</i> , 2013, 14, 6.	4.4	5
255	Genetics of Coagulation: What the Cardiologist Needs to Know. <i>Canadian Journal of Cardiology</i> , 2013, 29, 75-88.	0.8	7
256	Selective D-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2013, 158, 93.	2.0	73
257	Targeted Gene Sequencing Identifies Variants in the Protein C and Endothelial Protein C Receptor Genes in Patients With Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2674-2681.	1.1	12
258	Strain history dependence of the nonlinear stress response of fibrin and collagen networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12197-12202.	3.3	224
259	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
260	Zn ²⁺ Mediates High Affinity Binding of Heparin to the Î±C Domain of Fibrinogen. <i>Journal of Biological Chemistry</i> , 2013, 288, 29394-29402.	1.6	21
261	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	1.0	59
262	Apixaban for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 699-708.	13.9	1,116
263	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
264	Procoagulants for management of bleeding with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2013, 110, 01.	1.8	11
265	Novel oral anticoagulants in gastroenterology practice. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 227-239.	0.5	94
266	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915
267	Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. <i>Circulation</i> , 2013, 128, 1179-1181.	1.6	47
268	The Real Decoy. <i>Circulation Research</i> , 2013, 113, 954-957.	2.0	19
269	Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin. <i>Journal of Biological Chemistry</i> , 2013, 288, 16862-16871.	1.6	38
270	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	1.8	154

#	ARTICLE	IF	CITATIONS
271	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
272	Dabigatran monitoring made simple?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 393-395.	1.8	9
273	Gastrointestinal bleeding with the new oral anticoagulants â€“ defining the issues and the management strategies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 205-212.	1.8	155
274	Venous Thrombosis. , 2013, , 619-626.		0
275	Zinc: An important cofactor in haemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 421-430.	1.8	89
276	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. <i>Blood</i> , 2013, 122, 211-211.	0.6	15
277	Extended treatment of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 302-4.	0.3	0
278	More on Acutely Injured Patients Receiving Dabigatran. <i>New England Journal of Medicine</i> , 2012, 366, 863-864.	13.9	5
279	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. <i>Circulation</i> , 2012, 126, 2428-2432.	1.6	105
280	Warfarin After Bioprosthetic Aortic Valve Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2147.	3.8	6
281	New Antithrombotic Drugs. <i>Chest</i> , 2012, 141, e120S-e151S.	0.4	284
282	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet, The</i> , 2012, 379, 96-98.	6.3	2
283	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	2.0	61
284	Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. <i>Critical Care</i> , 2012, 16, R151.	2.5	225
285	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	0.4	13
286	By Increasing the Affinity of Heparin for Fibrin, Zn ²⁺ Promotes the Formation of a Ternary Heparinâ€“Thrombinâ€“Fibrin Complex That Protects Thrombin from Inhibition by Antithrombin. <i>Biochemistry</i> , 2012, 51, 7964-7973.	1.2	14
287	Oral Direct Factor Xa Inhibitors. <i>Circulation Research</i> , 2012, 111, 1069-1078.	2.0	92
288	Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. <i>Canadian Journal of Cardiology</i> , 2012, 28, 6-8.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. <i>Acta Biomaterialia</i> , 2012, 8, 4092-4100.	4.1	68
290	A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2012, 287, 4652-4661.	1.6	35
291	Dabigatran and risk of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 260-262.	6.1	30
292	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
293	Modification of Polyurethane with Polyethylene Glycolâ€“Corn Trypsin Inhibitor for Inhibition of Factor XIIa in Blood Contact. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2012, 23, 1981-1993.	1.9	12
294	New oral anticoagulants: which one should my patient use?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 536-540.	0.9	37
295	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.4	318
296	Parenteral Anticoagulants. <i>Chest</i> , 2012, 141, e24S-e43S.	0.4	839
297	Dual surface modification with PEG and corn trypsin inhibitor: Effect of PEG:CTI ratio on protein resistance and anticoagulant properties. <i>Journal of Biomedical Materials Research - Part A</i> , 2012, 100A, 856-862.	2.1	11
298	New oral anticoagulants: A view from the laboratory. <i>American Journal of Hematology</i> , 2012, 87, S133-6.	2.0	30
299	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. <i>Blood</i> , 2012, 120, LBA-1-LBA-1.	0.6	4
300	New oral anticoagulants: which one should my patient use?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 536-40.	0.9	8
301	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. <i>Blood</i> , 2011, 118, 6667-6674.	0.6	83
302	Hypercoagulable States. <i>Critical Care Clinics</i> , 2011, 27, 933-952.	1.0	50
303	Histidine-rich Glycoprotein Binds Fibrin(ogen) with High Affinity and Competes with Thrombin for Binding to the Î³â€“Chain. <i>Journal of Biological Chemistry</i> , 2011, 286, 30314-30323.	1.6	27
304	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 365, 2167-2177.	13.9	512
305	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011, 127, S5-S12.	0.8	64
306	Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. <i>Blood</i> , 2011, 117, 4134-4141.	0.6	54

#	ARTICLE	IF	CITATIONS
307	Surface modification with polyethylene glycol- α -corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. <i>Acta Biomaterialia</i> , 2011, 7, 4177-4186.	4.1	21
308	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.4	13
309	Importance of Family History as a Risk Factor for Venous Thromboembolism. <i>Circulation</i> , 2011, 124, 996-997.	1.6	10
310	Assays for Measuring Rivaroxaban: Their Suitability and Limitations. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 673-679.	1.0	148
311	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	1.8	311
312	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. <i>Thrombosis and Haemostasis</i> , 2010, 104, 642-649.	1.8	144
313	New and Emerging Anticoagulant Therapies for Venous Thromboembolism. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 142-155.	0.4	5
314	Update on heparin: what do we need to know?. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 199-207.	1.0	59
315	Meeting the Unmet Needs in Anticoagulant Therapy. <i>European Journal of Haematology</i> , 2010, 85, 1-28.	1.1	87
316	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2010, 103, 481-483.	1.8	6
317	A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1150-1157.	1.8	34
318	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	1.6	262
319	Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores. <i>Journal of Biological Chemistry</i> , 2010, 285, 28912-28923.	1.6	39
320	HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. <i>Thrombosis and Haemostasis</i> , 2010, 103, 83-96.	1.8	26
321	New oral anticoagulants in development. <i>Thrombosis and Haemostasis</i> , 2010, 103, 62-70.	1.8	101
322	Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl)oxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models. <i>Thrombosis Research</i> , 2010, 126, e383-e388.	0.8	15
323	Potential of new anticoagulants in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S30-S35.	0.8	14
324	Role of the tissue factor pathway in the biology of tumor initiating cells. <i>Thrombosis Research</i> , 2010, 125, S44-S50.	0.8	38

#	ARTICLE	IF	CITATIONS
325	Hypercoagulable States. <i>Clinics in Chest Medicine</i> , 2010, 31, 659-673.	0.8	31
326	Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1212-1218.	1.8	7
327	Anticoagulation for ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1186-1188.	1.6	5
328	Long Range Communication between Exosites 1 and 2 Modulates Thrombin Function. <i>Journal of Biological Chemistry</i> , 2009, 284, 25620-25629.	1.6	63
329	G-Proteinâ€‘Coupled Receptors as Signaling Targets for Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 449-457.	1.1	102
330	Prevention and treatment of venous thromboembolism during pregnancy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, S22-6.	0.7	3
331	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 366-380.	1.0	24
332	Comparative Pharmacodynamics and Pharmacokinetics of Oralâ€‘Direct Thrombin andâ€‘Factorâ€‘Xa Inhibitors in Development. <i>Clinical Pharmacokinetics</i> , 2009, 48, 1-22.	1.6	466
333	Inferior Vena Cava Ligation Rapidly Induces Tissue Factor Expression and Venous Thrombosis in Rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 863-869.	1.1	90
334	Unanswered questions in venous thromboembolism. <i>Thrombosis Research</i> , 2009, 123, S2-S10.	0.8	16
335	Otamixaban in acute coronary syndromes. <i>Lancet, The</i> , 2009, 374, 762-764.	6.3	8
336	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 2-4.	1.8	25
337	Overview of New Anticoagulant Drugs. <i>Fundamental and Clinical Cardiology</i> , 2009, , 133-154.	0.0	0
338	Inhibition of osteolytic bone metastasis by unfractionated heparin. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 903-911.	1.7	8
339	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet, The</i> , 2008, 372, 6-8.	6.3	12
340	New Anticoagulants for Treatment of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 380-386.	1.1	168
341	Contribution of Host-Derived Tissue Factor to Tumor Neovascularization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1975-1981.	1.1	79
342	Bivalent Binding to β A/ β 2-Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 2008, 283, 2470-2477.	1.6	54

#	ARTICLE	IF	CITATIONS
343	Parenteral Anticoagulants. Chest, 2008, 133, 141S-159S.	0.4	674
344	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood, 2008, 112, 4432-4436.	0.6	103
345	New Antithrombotic Drugs. Chest, 2008, 133, 234S-256S.	0.4	235
346	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thrombosis and Haemostasis, 2008, 100, 1058-1067.	1.8	33
347	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. Blood, 2008, 112, 33-33.	0.6	20
348	Laboratory assessment of platelet function and coagulation. , 2008, , 19-31.		0
349	A Replacement for Warfarin. Circulation, 2007, 116, 131-133.	1.6	40
350	Anticoagulants in heart disease: current status and perspectives. European Heart Journal, 2007, 28, 880-913.	1.0	119
351	Emerging Anticoagulant Drugs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 721-721.	1.1	2
352	In the Presence of Phospholipids, Glycosaminoglycans Potentiate Factor Xa-Mediated Protein C Activation by Modulating Factor Xa Activity. Biochemistry, 2007, 46, 4195-4203.	1.2	5
353	Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opinion on Investigational Drugs, 2007, 16, 271-282.	1.9	64
354	Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition.. Blood, 2007, 110, 2691-2691.	0.6	1
355	Incorporation of Fragment X into Fibrin Clots Renders Them More Susceptible to Lysis by Plasmin. Biochemistry, 2006, 45, 4257-4265.	1.2	13
356	A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. Thrombosis and Haemostasis, 2006, 96, 802-806.	1.8	19
357	Emerging themes in the treatment of venous thromboembolism. Thrombosis and Haemostasis, 2006, 96, 239-241.	1.8	2
358	Emerging anticoagulants for the treatment of venous thromboembolism. Thrombosis and Haemostasis, 2006, 96, 274-284.	1.8	93
359	Initial treatment of venous thromboembolism. Thrombosis and Haemostasis, 2006, 96, 242-250.	1.8	13
360	OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 478-479.	3.3	1

#	ARTICLE	IF	CITATIONS
361	An Evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2006, 144, 812.	2.0	159
362	The status of new anticoagulants. <i>British Journal of Haematology</i> , 2006, 134, 3-19.	1.2	92
363	HD1, a Thrombin-directed Aptamer, Binds Exosite 1 on Prothrombin with High Affinity and Inhibits Its Activation by Prothrombinase. <i>Journal of Biological Chemistry</i> , 2006, 281, 37477-37485.	1.6	59
364	Changing Paradigms in the Management of Venous Thromboembolism. <i>The American Heart Hospital Journal</i> , 2006, 4, 135-141.	0.2	0
365	Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway. <i>Journal of Biological Chemistry</i> , 2006, 281, 20780-20787.	1.6	19
366	Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. <i>Blood</i> , 2006, 108, 193-193.	0.6	0
367	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. <i>Blood</i> , 2005, 105, 1734-1741.	0.6	512
368	New anticoagulants. <i>Blood</i> , 2005, 105, 453-463.	0.6	155
369	New anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1843-1853.	1.9	172
370	New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. <i>British Journal of Pharmacology</i> , 2005, 144, 1017-1028.	2.7	44
371	Pharmacology and Clinical Potential of Direct Thrombin Inhibitors. <i>Current Pharmaceutical Design</i> , 2005, 11, 3877-3884.	0.9	25
372	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 1390-1397.	1.6	113
373	Coagulation Assays. <i>Circulation</i> , 2005, 112, e53-60.	1.6	170
374	Emerging therapies for stroke prevention in atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C19-C27.	0.8	6
375	New Anticoagulant Therapy. <i>Annual Review of Medicine</i> , 2005, 56, 63-77.	5.0	31
376	Zinc ²⁺ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.. <i>Blood</i> , 2005, 106, 1956-1956.	0.6	1
377	Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.. <i>Blood</i> , 2005, 106, 1950-1950.	0.6	0
378	Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1090-1096.	1.8	89

#	ARTICLE	IF	CITATIONS
379	Localization of heparin and low-molecular-weight heparin in the rat kidney. <i>Thrombosis and Haemostasis</i> , 2004, 91, 927-934.	1.8	7
380	Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 21-30.	1.5	51
381	New Anticoagulants for Treatment of Venous Thromboembolism. <i>Circulation</i> , 2004, 110, I-19-I-26.	1.6	50
382	Ximelagatran: the first oral direct thrombin inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 403-413.	1.9	26
383	Management of Venous Thromboembolism: Present and Future. <i>Circulation</i> , 2004, 110, I-2-I-2.	1.6	0
384	Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 743-749.	1.9	133
385	Modes and consequences of thrombin's interaction with fibrin. <i>Biophysical Chemistry</i> , 2004, 112, 277-284.	1.5	18
386	Thrombophilia and New Anticoagulant Drugs. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 424-438.	0.9	35
387	Antithrombotic Therapy During Percutaneous Coronary Intervention. <i>Chest</i> , 2004, 126, 576S-599S.	0.4	220
388	Patients with severe sepsis vary markedly in their ability to generate activated protein C. <i>Blood</i> , 2004, 104, 3958-3964.	0.6	147
389	New Anticoagulant Drugs. <i>Chest</i> , 2004, 126, 265S-286S.	0.4	142
390	Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.. <i>Blood</i> , 2004, 104, 1721-1721.	0.6	0
391	Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa.. <i>Blood</i> , 2004, 104, 1724-1724.	0.6	0
392	No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.. <i>Blood</i> , 2004, 104, 2979-2979.	0.6	0
393	Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.. <i>Blood</i> , 2004, 104, 1737-1737.	0.6	0
394	Direct Thrombin Inhibitors in Cardiac Disease. <i>Cardiovascular Toxicology</i> , 2003, 3, 13-26.	1.1	28
395	Glycosaminoglycans Bind Factor Xa in a Ca ²⁺ -Dependent Fashion and Modulate Its Catalytic Activity. <i>Biochemistry</i> , 2003, 42, 13091-13098.	1.2	9
396	A novel approach to thrombin inhibition. <i>Thrombosis Research</i> , 2003, 109, S17-S22.	0.8	50

#	ARTICLE	IF	CITATIONS
397	Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. <i>Nuclear Medicine and Biology</i> , 2003, 30, 61-72.	0.3	37
398	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2003, 349, 631-639.	13.9	728
399	New Anticoagulants. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 201-209.	1.0	25
400	Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide. <i>Journal of Biological Chemistry</i> , 2003, 278, 35767-35774.	1.6	39
401	Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin. <i>Journal of Biological Chemistry</i> , 2003, 278, 21584-21591.	1.6	66
402	Heparin and Angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1954-1955.	1.1	21
403	Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin. <i>Circulation Research</i> , 2003, 93, 1120-1126.	2.0	28
404	Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 2003, 278, 23398-23409.	1.6	26
405	Emerging Anticoagulant Drugs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1491-1500.	1.1	29
406	New Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 619-632.	1.5	19
407	A Diagnostic Strategy Involving a Quantitative Latex α -Dimer Assay Reliably Excludes Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2003, 138, 787.	2.0	120
408	Neutrophils and the protein C pathway. <i>Blood</i> , 2003, 102, 1152-1153.	0.6	1
409	Heparan sulfate: Antithrombotic or not?. <i>Journal of Clinical Investigation</i> , 2003, 111, 952-954.	3.9	37
410	Heparan sulfate: Antithrombotic or not?. <i>Journal of Clinical Investigation</i> , 2003, 111, 952-954.	3.9	19
411	Thromboprophylaxis in surgical patients. <i>Canadian Journal of Surgery</i> , 2003, 46, 129-35.	0.5	44
412	Direct Thrombin Inhibitors in Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1004-1011.	1.6	128
413	Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface. <i>Journal of Biological Chemistry</i> , 2002, 277, 7529-7539.	1.6	108
414	Incorporation of Vitronectin into Fibrin Clots. <i>Journal of Biological Chemistry</i> , 2002, 277, 7520-7528.	1.6	63

#	ARTICLE	IF	CITATIONS
415	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	1.6	1,040
416	The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κ B and Mitogen-activated Protein Kinase Pathways. <i>Journal of Experimental Medicine</i> , 2002, 196, 565-577.	4.2	325
417	Identification of Dp71 Isoforms in the Platelet Membrane Cytoskeleton. <i>Journal of Biological Chemistry</i> , 2002, 277, 47106-47113.	1.6	26
418	Antithrombin-Heparin Covalent Complex. <i>Circulation</i> , 2002, 106, 261-265.	1.6	35
419	Direct thrombin inhibitors. <i>Thrombosis Research</i> , 2002, 106, V275-V284.	0.8	131
420	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. <i>Thrombosis Research</i> , 2002, 107, 241-244.	0.8	66
421	Low-dose warfarin in rehabilitating stroke survivors. <i>Thrombosis Research</i> , 2002, 107, 287-290.	0.8	15
422	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. <i>Lancet</i> , The, 2002, 359, 294-302.	6.3	251
423	Antithrombin-Independent Anticoagulation by Hypersulfated Low-Molecular-Weight Heparin. <i>Trends in Cardiovascular Medicine</i> , 2002, 12, 281-287.	2.3	6
424	Acute coronary syndromes: a focus on thrombin. <i>Journal of Invasive Cardiology</i> , 2002, 14 Suppl B, 2B-7B.	0.4	3
425	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International) Tj ETQq1 1 0.784314 rgBT /@verlock		
426	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2001, 85, 390-394.	1.8	69
427	Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and D-dimer Testing. <i>Annals of Internal Medicine</i> , 2001, 135, 108.	2.0	179
428	New Anticoagulant Drugs. <i>Chest</i> , 2001, 119, 95S-107S.	0.4	153
429	New anticoagulant drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 7-17.	1.0	3
430	Characterization of a Mouse Model for Thrombomodulin Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1531-1537.	1.1	138
431	Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Chest</i> , 2001, 119, 321S-336S.	0.4	93
432	Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin. <i>Archives of Internal Medicine</i> , 2001, 161, 385.	4.3	72

#	ARTICLE	IF	CITATIONS
433	Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin. <i>Journal of Biological Chemistry</i> , 2001, 276, 20959-20965.	1.6	88
434	Conformational Changes in Thrombin When Complexed by Serpins. <i>Journal of Biological Chemistry</i> , 2001, 276, 44828-44834.	1.6	26
435	Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 9755-9761.	1.6	23
436	Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. <i>Circulation</i> , 2001, 103, 643-650.	1.6	43
437	Beyond Heparin and Aspirin. <i>Archives of Internal Medicine</i> , 2000, 160, 749.	4.3	37
438	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. <i>Thrombosis and Haemostasis</i> , 2000, 83, 416-420.	1.8	1,417
439	Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin. <i>Journal of Biological Chemistry</i> , 2000, 275, 19788-19794.	1.6	61
440	Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2000, 275, 36612-36620.	1.6	22
441	Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2000, 343, 1439-1444.	13.9	409
442	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	18
443	Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2000, 275, 10112-10120.	1.6	54
444	The Asp272â€“Glu282 Region of Platelet Glycoprotein Ib β Interacts with the Heparin-binding Site of β -Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III. <i>Journal of Biological Chemistry</i> , 2000, 275, 3887-3895.	1.6	61
445	Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. <i>Nuclear Medicine and Biology</i> , 2000, 27, 289-297.	0.3	122
446	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet</i> , The, 2000, 355, 1936-1942.	6.3	419
447	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	2
448	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	0
449	Mechanism of Action of Plasminogen Activators. <i>Thrombosis and Haemostasis</i> , 1999, 82, 974-982.	1.8	37
450	Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. <i>Blood</i> , 1999, 93, 3442-3450.	0.6	39

#	ARTICLE	IF	CITATIONS
451	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , 1999, 93, 1231-1236.	0.6	69
452	Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. <i>Blood</i> , 1999, 94, 959-967.	0.6	324
453	Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II. <i>Journal of Biological Chemistry</i> , 1999, 274, 6226-6233.	1.6	72
454	Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II. <i>Journal of Biological Chemistry</i> , 1999, 274, 27597-27604.	1.6	49
455	Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. <i>Circulation</i> , 1999, 99, 682-689.	1.6	33
456	Deep vein thrombosis. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 43-53.	0.4	1
457	New antithrombotic agents. <i>Lancet</i> , The, 1999, 353, 1431-1436.	6.3	111
458	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1999, 340, 901-907.	13.9	1,052
459	Clinical Utility of a Rapid Whole-Blood D-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 1999, 131, 417.	2.0	113
460	New Antithrombotic Drugs: Beyond Aspirin and Heparin. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999, 29, 68-68.	0.5	0
461	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , 1999, 93, 1231-1236.	0.6	1
462	Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. <i>American Journal of Cardiology</i> , 1998, 82, 12P-18P.	0.7	98
463	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. <i>Translational Research</i> , 1998, 132, 181-185.	2.4	21
464	A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. <i>Journal of Internal Medicine</i> , 1998, 243, 15-23.	2.7	117
465	Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E. <i>Journal of Biological Chemistry</i> , 1998, 273, 18292-18299.	1.6	37
466	Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 1998, 98, 1064-1070.	1.6	107
467	Localization of the Thrombin-binding Domain on Prothrombin Fragment 2. <i>Journal of Biological Chemistry</i> , 1998, 273, 8932-8939.	1.6	29
468	Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors. <i>Circulation</i> , 1998, 97, 544-552.	1.6	198

#	ARTICLE	IF	CITATIONS
469	Homocysteine-dependent Alterations in Mitochondrial Gene Expression, Function and Structure. <i>Journal of Biological Chemistry</i> , 1998, 273, 30808-30817.	1.6	69
470	Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 1998, 273, 34730-34736.	1.6	50
471	New Antithrombotic Agents. <i>Chest</i> , 1998, 114, 715S-727S.	0.4	31
472	The new heparins. <i>Coronary Artery Disease</i> , 1998, 9, 65-74.	0.3	2
473	Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 1998, 129, 1006.	2.0	215
474	Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 1998, 129, 997.	2.0	835
475	Characterization of the stress-inducing effects of homocysteine. <i>Biochemical Journal</i> , 1998, 332, 213-221.	1.7	221
476	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. <i>Thrombosis and Haemostasis</i> , 1998, 80, 413-417.	1.8	100
477	Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1997, 337, 657-662.	13.9	731
478	Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin. <i>Journal of Biological Chemistry</i> , 1997, 272, 25493-25499.	1.6	98
479	Low-Molecular-Weight Heparins. <i>New England Journal of Medicine</i> , 1997, 337, 688-698.	13.9	1,520
480	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. <i>Blood</i> , 1997, 89, 3236-3242.	0.6	163
481	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. <i>Translational Research</i> , 1997, 130, 649-655.	2.4	49
482	Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes. <i>Advances in Experimental Medicine and Biology</i> , 1997, 425, 55-66.	0.8	16
483	Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. <i>Circulation</i> , 1997, 95, 118-124.	1.6	64
484	A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1996, 334, 677-681.	13.9	1,157
485	Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. <i>Thrombosis and Haemostasis</i> , 1996, 75, 529-535.	1.8	2
486	More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. <i>Thrombosis and Haemostasis</i> , 1996, 76, 0902-0908.	1.8	157

#	ARTICLE	IF	CITATIONS
487	Interaction of low molecular weight heparin with ketorolac. <i>Translational Research</i> , 1996, 127, 583-587.	2.4	11
488	Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 1996, 75, 551-554.	1.8	7
489	Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. <i>Circulation</i> , 1996, 94, 3026-3049.	1.6	755
490	Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma. <i>Pediatric Research</i> , 1996, 39, 826-830.	1.1	26
491	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. <i>Chest</i> , 1995, 108, 486S-501S.	0.4	56
492	New Antithrombotics. <i>Chest</i> , 1995, 108, 471S-485S.	0.4	37
493	Activation of blood coagulation by plaque rupture: Mechanisms and prevention. <i>American Journal of Cardiology</i> , 1995, 75, 18B-22B.	0.7	29
494	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1995, 74, 606-611.	1.8	351
495	Accuracy of clinical assessment of deep-vein thrombosis. <i>Lancet, The</i> , 1995, 345, 1326-1330.	6.3	705
496	Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding. <i>Journal of Vascular and Interventional Radiology</i> , 1995, 6, 19S-23S.	0.2	24
497	FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 60, 144-146.	0.5	13
498	A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. <i>Circulation</i> , 1995, 91, 2184-2187.	1.6	203
499	New Anticoagulant Strategies. <i>Drugs</i> , 1994, 48, 485-497.	4.9	41
500	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , 1994, 71, 300-304.	1.8	150
501	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993, 70, 443-447.	1.8	6
502	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. <i>Thrombosis and Haemostasis</i> , 1993, 70, 625-630.	1.8	97
503	Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. <i>Thrombosis and Haemostasis</i> , 1993, 69, 418-421.	1.8	22
504	Thrombin/Antithrombin III Complex Formation in the Neonatal Respiratory Distress Syndrome. <i>The American Review of Respiratory Disease</i> , 1992, 145, 767-770.	2.9	39

#	ARTICLE	IF	CITATIONS
505	Antithrombins: Their Potential as Antithrombotic Agents. Annual Review of Medicine, 1992, 43, 9-16.	5.0	14
506	Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. Thrombosis and Haemostasis, 1992, 67, 542-544.	1.8	27
507	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. Thrombosis and Haemostasis, 1992, 68, 064-068.	1.8	50
508	Development and Application of Assays for Elastase-Specific Fibrinogen Fragments. Annals of the New York Academy of Sciences, 1991, 624, 154-166.	1.8	4
509	CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1044-1048.	3.3	251
510	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. British Journal of Haematology, 1991, 79, 296-301.	1.2	14
511	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinolysis. Thrombosis and Haemostasis, 1991, 65, 541-544.	1.8	10
512	Effect of Fibrinogen Degradation Products and Lung Ground Substance on Surfactant Function. Neonatology, 1990, 57, 325-333.	0.9	35
513	Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry, 1990, 29, 8424-8429.	1.2	266
514	Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.. Journal of Clinical Investigation, 1990, 86, 385-391.	3.9	1,036
515	Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 7734-7738.	3.3	406
516	Dysfibrinogenemia in Obstructive Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 967-970.	0.9	6
517	Increased Neutrophil Elastase Activity in Cigarette Smokers. Annals of Internal Medicine, 1987, 107, 680.	2.0	104
518	Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. Thrombosis and Haemostasis, 1986, 56, 198-201.	1.8	35
519	Ximelagatran: the first oral direct thrombin inhibitor. , 0, .		1
520	Trends in the proportion of women as reviewers, editors, and editorial board members of 15 North American and British medical journals from 2014 to 2019: A retrospective study. European Science Editing, 0, 48, .	0.0	0